Brain Biomarker Interpretation in ASD Using Deep Learning and fMRI

Xiaoxiao Li, Nicha C. Dvornek, Juntang Zhuang, Pamela Ventola, James S. Duncan

TL;DR

This paper introduces a two-stage deep learning pipeline designed to not only classify Autism Spectrum Disorder (ASD) from fMRI data but also to "peek under the hood" and identify the specific brain biomarkers driving those decisions. By combining a 3D Convolutional Neural Network (CNN) with a novel frequency-normalized sampling strategy for image corruption, the researchers can statistically pinpoint which regions of interest (ROIs) are most critical for distinguishing ASD from neurotypical controls.

What Problem Does This Paper Address?

While Deep Neural Networks (DNNs) have shown great promise in identifying ASD using functional Magnetic Resonance Imaging (fMRI), they are notoriously "black boxes." For a clinician, a high accuracy score is insufficient; they need to understand which brain regions are abnormal to provide targeted treatment and early diagnosis.

Existing visualization techniques (like gradient ascent or saliency maps) often produce blurry, imprecise results that are difficult to map back to specific anatomical structures. Furthermore, fMRI datasets are often small and imbalanced, which can lead to biased interpretations if standard visualization methods are used. This paper seeks to bridge the gap between high-performance deep learning and interpretable clinical biomarkers.

Methods

The authors propose a two-stage pipeline:

  1. Classification: They train a 3D CNN (specifically a "2CC3D" model) on 4D fMRI data. To handle the temporal aspect of fMRI, they convert the 4D sequence into 2-channel 3D images representing the mean and standard deviation of voxel intensity over a sliding window.
  2. Interpretation (The "Corrupting Strategy"): To find important biomarkers, the researchers systematically "corrupt" specific Regions of Interest (ROIs) based on the AAL brain atlas.
  3. Frequency-Normalized Sampling: Instead of just blacking out a region (which creates unnatural artifacts), they replace an ROI with samples from other subjects. They use a weighting system based on Pearson correlation to ensure the "corrupted" data is representative and to prevent bias if one class (e.g., ASD) has more samples than the other.
  4. Statistical Validation: They pass these corrupted images back through the trained DNN. If the model’s prediction changes significantly (measured via Jensen-Shannon Divergence and Wilcoxon signed-rank tests), that ROI is flagged as a significant biomarker.

Datasets

The study utilizes three distinct datasets:

  • Synthetic Data: A custom-generated dataset used to prove that their frequency-normalized sampling can correctly identify important features even when the training data is heavily biased.
  • Biopoint Dataset: Task-based fMRI from 82 children with ASD and 48 age/IQ-matched controls performing a "biological motion" task.
  • ABIDE I (University of Michigan site): Resting-state fMRI from 41 ASD subjects and 54 healthy controls.

Key Insights and Ideas

  • Anatomical Grounding: Unlike standard computer vision saliency maps, this method leverages the AAL brain atlas, ensuring that the identified "features" correspond to known anatomical regions.
  • Biomarker Categorization: The method allows researchers to categorize ROIs into three groups: those important for identifying ASD, those important for identifying controls, and those significant for both.
  • Handling Bias: The "aha moment" in their sampling strategy is the use of frequency normalization. By weighting samples, they ensure that the interpretation isn't skewed by the fact that one group might be more easily sampled than another.
  • Consistency Across States: The model found common biomarkers (like the precuneus and frontal regions) across both task-based and resting-state fMRI, suggesting these are robust indicators of ASD regardless of what the patient is doing during the scan.

Key Results

  • High Accuracy: The 2CC3D model achieved 87.1% accuracy on the Biopoint dataset and 85.3% accuracy on the ABIDE dataset.
  • Neurological Relevance: The biomarkers identified—such as regions related to the "default mode network," functional connectivity, and motor processing (finger movement)—align closely with existing neurological literature on ASD.
  • Superior Interpretation: In synthetic tests, the frequency-normalized approach correctly identified important patches that standard equal-weighting methods missed due to data imbalance.

Limitations and Future Work

The authors acknowledge that their current method relies on a pre-defined brain atlas (AAL) to define ROIs. While this provides anatomical clarity, it might miss smaller, sub-ROI features.

Future work could involve using more sophisticated generative models (like GANs) to create the "corrupted" images, potentially leading to even more precise localization of biomarkers. Additionally, while the model is robust, the authors suggest that further validation on even larger, multi-site datasets would be beneficial to ensure the biomarkers generalize across different scanning environments.

Summary updated

Abstract

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder. Finding the biomarkers associated with ASD is extremely helpful to understand the underlying roots of the disorder and can lead to earlier diagnosis and more targeted treatment. Although Deep Neural Networks (DNNs) have been applied in functional magnetic resonance imaging (fMRI) to identify ASD, understanding the data driven computational decision making procedure has not been previously explored. Therefore, in this work, we address the problem of interpreting reliable biomarkers associated with identifying ASD; specifically, we propose a 2-stage method that classifies ASD and control subjects using fMRI images and interprets the saliency features activated by the classifier. First, we trained an accurate DNN classifier. Then, for detecting the biomarkers, different from the DNN visualization works in computer vision, we take advantage of the anatomical structure of brain fMRI and develop a frequency-normalized sampling method to corrupt images. Furthermore, in the ASD vs. control subjects classification scenario, we provide a new approach to detect and characterize important brain features into three categories. The biomarkers we found by the proposed method are robust and consistent with previous findings in the literature. We also validate the detected biomarkers by neurological function decoding and comparing with the DNN activation maps.
BibTeX
@inproceedings{li2018brain,
  author = {Xiaoxiao Li and Nicha C. Dvornek and Juntang Zhuang and Pamela Ventola and James S. Duncan},
  title = {{Brain Biomarker Interpretation in ASD Using Deep Learning and fMRI}},
  booktitle = {International Conference on Medical Image Computing and Computer-Assisted Intervention},
  year = {2018},
  doi = {10.1007/978-3-030-00931-1\_24},
}

Loading related content...

Figure